Bristol Myers Earnings Are ‘a Tale of 2 Trends’ as Guidance Falls Short
The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...
FiercePharma20h
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs
BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...
Bristol Adds to Cost Cutting With Outlook Missing Estimates
Bristol Myers Squibb Co. released sales and profit forecasts for 2025 below Wall Street’s expectations — a sign the company’s ...
BioSpace18h
BMS’ Cobenfy Sales Begin, With Launch Full Speed Ahead
Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb & Co (NYSE:BMY) posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 ...
BioPharma Dive15h
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...
These Stocks Are Moving the Most Today: Qualcomm, Lilly, Skyworks, Ford, Honeywell, Strategy, Roblox, Bristol Myers, Amazon, and More
Qualcomm trades lower after earnings, Eli Lilly stock rises on upbeat guidance, Skyworks says its share of the business to ...
Eli Lilly, Bristol Myers Squibb, Peloton: Market Minute
Yahoo Finance Anchor Josh Lipton recaps the top stories on Wall Street as part of today's Market Minute. US stocks (^DJI, ...